Sage Therapeutics' (SAGE) Hold Rating Reiterated at Needham & Company LLC

Needham & Company LLC reissued their hold rating on shares of Sage Therapeutics (NASDAQ:SAGE - Free Report) in a research report report published on Wednesday,Benzinga reports.

SAGE has been the subject of a number of other research reports. Scotiabank reduced their price objective on Sage Therapeutics from $17.00 to $14.00 and set a "sector outperform" rating for the company in a research report on Wednesday, October 30th. Piper Sandler reduced their price objective on Sage Therapeutics from $26.00 to $9.00 and set an "overweight" rating for the company in a research report on Thursday, January 2nd. Stifel Nicolaus reduced their price objective on Sage Therapeutics from $10.00 to $6.00 and set a "hold" rating for the company in a research report on Monday, December 16th. StockNews.com downgraded Sage Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, October 31st. Finally, Oppenheimer reduced their price objective on Sage Therapeutics from $9.00 to $8.00 and set a "market perform" rating for the company in a research report on Wednesday, October 30th. Three investment analysts have rated the stock with a sell rating, sixteen have issued a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $9.65.

Sage Therapeutics Trading Down 0.6 %

NASDAQ:SAGE traded down $0.04 during mid-day trading on Wednesday, hitting $7.14. 1,943,315 shares of the company's stock traded hands, compared to its average volume of 2,832,859. The firm has a 50 day moving average of $6.40 and a two-hundred day moving average of $6.91. Sage Therapeutics has a 12 month low of $4.62 and a 12 month high of $26.25. The firm has a market capitalization of $436.75 million, a price-to-earnings ratio of -1.28 and a beta of 0.94.

Sage Therapeutics (NASDAQ:SAGE - Get Free Report) last announced its earnings results on Tuesday, February 11th. The biopharmaceutical company reported ($1.56) earnings per share for the quarter, missing the consensus estimate of ($1.54) by ($0.02). Sage Therapeutics had a negative net margin of 317.29% and a negative return on equity of 50.29%. As a group, equities research analysts expect that Sage Therapeutics will post -6.46 earnings per share for the current year.

Institutional Investors Weigh In On Sage Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Inspire Investing LLC increased its stake in shares of Sage Therapeutics by 77.0% in the 3rd quarter. Inspire Investing LLC now owns 57,772 shares of the biopharmaceutical company's stock valued at $417,000 after buying an additional 25,139 shares during the period. Creative Planning acquired a new stake in shares of Sage Therapeutics in the 3rd quarter valued at $88,000. Assenagon Asset Management S.A. increased its stake in shares of Sage Therapeutics by 11.3% in the 3rd quarter. Assenagon Asset Management S.A. now owns 186,039 shares of the biopharmaceutical company's stock valued at $1,343,000 after buying an additional 18,814 shares during the period. China Universal Asset Management Co. Ltd. increased its stake in shares of Sage Therapeutics by 66.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,742 shares of the biopharmaceutical company's stock valued at $85,000 after buying an additional 4,672 shares during the period. Finally, Harbor Capital Advisors Inc. increased its stake in shares of Sage Therapeutics by 21.7% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 45,738 shares of the biopharmaceutical company's stock valued at $330,000 after buying an additional 8,166 shares during the period. 99.22% of the stock is owned by institutional investors and hedge funds.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.